Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Cash & Current Investments (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Cash & Current Investments for 6 consecutive years, with $90.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Current Investments fell 7.99% year-over-year to $90.9 million, compared with a TTM value of $90.9 million through Dec 2025, down 7.99%, and an annual FY2025 reading of $90.9 million, down 7.99% over the prior year.
  • Cash & Current Investments was $90.9 million for Q4 2025 at Cytek Biosciences, down from $93.3 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $376.8 million in Q3 2021 and bottomed at $30000.0 in Q2 2024.
  • Average Cash & Current Investments over 5 years is $172.4 million, with a median of $161.7 million recorded in 2021.
  • The sharpest move saw Cash & Current Investments plummeted 99.99% in 2024, then soared 302603.14% in 2025.
  • Year by year, Cash & Current Investments stood at $364.6 million in 2021, then decreased by 17.86% to $299.5 million in 2022, then plummeted by 44.03% to $167.6 million in 2023, then plummeted by 41.09% to $98.7 million in 2024, then decreased by 7.99% to $90.9 million in 2025.
  • Business Quant data shows Cash & Current Investments for CTKB at $90.9 million in Q4 2025, $93.3 million in Q3 2025, and $75.5 million in Q2 2025.